S-1/A: Silexion Therapeutics Eyes $5 Million in Best-Efforts Offering to Advance Cancer Treatments

Silexion Therapeutics launches a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies, including SIL-204B for pancreatic cancer.

Summary

• Silexion Therapeutics is undertaking a best-efforts offering to raise up to $2,577,320 through ordinary shares and warrants, with an option for pre-funded warrants for certain investors.
• The offering aims to fund the development of SIL-204B, a treatment for KRAS-driven cancers, particularly locally advanced pancreatic cancer (LAPC).
• The combined public offering price is assumed at $1.94 per ordinary share and warrant, based on the closing price on January 10, 2025.
• H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a cash fee of 7.0% of gross proceeds, a management fee of 1.0% of gross proceeds, expense reimbursements, and warrants for 7% of the offered shares.
• The offering is set to terminate on February 1, 2025, and there is no minimum offering requirement.
• Silexion intends to use the net proceeds to advance pre-clinical and clinical studies and for general corporate purposes.
• The company is addressing Nasdaq compliance deficiencies related to minimum Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS), with deadlines in May 2025 to regain compliance.
• A 1-for-9 reverse share split was previously effected to address market value-related deficiencies.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the company's efforts to raise capital and advance its cancer treatments, it also acknowledges significant financial challenges, including net losses, going concern uncertainties, and Nasdaq compliance issues. The best-efforts nature of the offering and the lack of guaranteed funding contribute to a cautious outlook.

Positives

• The offering will provide capital to advance the development of SIL-204B, a promising treatment for KRAS-driven cancers.
• The company has a clear plan for using the proceeds, focusing on pre-clinical and clinical studies.
• Engagement of H.C. Wainwright & Co. as placement agent provides expertise in arranging the sale of securities.
• The option for pre-funded warrants allows investors with ownership limitations to participate in the offering.
• The company is actively addressing Nasdaq compliance deficiencies, demonstrating a commitment to maintaining its listing.

Negatives

• The offering is on a best-efforts basis, meaning there is no guarantee that the full $5 million will be raised.
• Failure to raise sufficient funds could limit the company's ability to pursue its business goals.
• The company has a history of net losses and will need to raise substantial additional funding in the future.
• The company is dependent on the success of its product candidates, which are in the early stages of development.
• The market may not be receptive to the company's product candidates based on a novel therapeutic modality.

Risks

• The company is a development-stage company with a limited operating history.
• The approach to discover and develop novel RNAi therapeutics is unproven for oncology.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company may find it difficult to enroll patients in its clinical studies.
• The company faces intense competition and rapid technological change.
• If the company fails to maintain compliance with Nasdaqs continued listing requirements, its securities may be delisted.
• The company's management team will have broad discretion over the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the warrants being offered or pre-funded warrants in this offering.
• The price of the company's ordinary shares and warrants may be volatile.

Future Outlook

The company plans to initiate toxicology studies of SIL-204B in 2025, followed by regulatory submission in the second half of 2025, to initiate a Phase 2/3 trial in the first half of 2026.

Industry Context

The document highlights the competitive landscape of the biotechnology and pharmaceutical industries, particularly in the oncology sector, with numerous companies developing treatments for KRAS mutations. It acknowledges the presence of major players like Bristol-Myers Squibb, Revolution Medicines, and AstraZeneca, indicating a dynamic and competitive environment for Silexion's product candidates.

Comparison to Industry Standards

• The document mentions competitors such as Bristol-Myers Squibb/Mirati, Amgen, AstraZeneca, E.I. Lilly, Pfizer, Novartis International AG, Takeda Pharmaceutical Company Limited, Alnylam, Revolutions Medicines, Boehringer Ingelheim, Biomea Fusion Inc, Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Silence Therapeutics plc, RXi Pharmaceuticals Corporation, Quark Pharmaceuticals, Inc. and Marina Biotech, Inc.
• These companies are developing novel drugs and technology platforms using technology similar or in the same field as Silexion's RNAi therapeutics.
• The document also mentions competition from companies working to develop antisense-based drugs, such as Ionis Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: Potential dilution from the offering and uncertainty regarding the company's ability to achieve its business goals.
• Employees: Uncertainty regarding the company's financial stability and ability to continue operations.
• Patients: Potential for new and improved treatments for KRAS-driven cancers if the company is successful in its development efforts.
• Investors: Potential for high returns if the company is successful, but also significant risk of loss due to the company's financial challenges and the inherent risks of drug development.

Next Steps

• Initiate toxicology studies of SIL-204B in 2025.
• Submit regulatory submission in the second half of 2025 to initiate the Phase 2/3 trial.
• Initiate Phase 2/3 trial in the first half of 2026.

Key Dates

Keywords

Silexion Therapeutics, best-efforts offering, RNAi therapeutics, SIL-204B, pancreatic cancer, KRAS, warrants, pre-funded warrants, H.C. Wainwright, capital raise, Nasdaq, MVLS, MVPHS, reverse share split, biotechnology, oncology